Table 2.

Toxicity, efficacy outcomes and the number of treated patients of erlotinib treatment.

	Response/toxicity (number of patients)
Publications	100 mg	150 mg	200 mg	250 mg
Toxicity
Prados et al.6	0 (3)	1 (3)	0 (3)	3 (6)
Raizer et al.9	–	11 (99)	–	–
Thepot et al.7	0 (5)	3 (25)	–	–
Calvo et al.8	–	1 (25)	–	–
Van den Bent et al.10	–	–	6 (54)	–
Sheikh and Chambers11	–	167 (307)	–	–
Clinical trial ROCHE NTC0053193412	–	11 (59)	–	–
${\gamma }_{\ell }^{(1)}$	0.13	0.24	0.40	0.59
${\gamma }_{\ell }^{(2)}$	0.07	0.19	0.34	0.49
${\gamma }_{\ell }^{(T)}$	0.09	0.21	0.36	0.54
Efficacy for glioblastoma at dose 150 mg
Prados et al.6		1 (16)
Prados et al.6 (EIAED)		5 (44)
Raizer et al.9		7 (53)
Yung et al.13		20 (48)

Note: Toxicities are skin rash of grade 3 or more and efficacy, defined as stable disease and above (RECIST), was limited to glioblastoma. The distributions for calculating the mixture ${\gamma }_{\ell }^{(T)}$ are given for each dose ℓ with the value of ${\gamma }_{\ell }^{(1)}$ based on adult PK information and the value of ${\gamma }_{\ell }^{(2)}$ built with adult toxicities.